Abstract
Latest clinical guidelines recommend biological prostheses as a reasonable choice in patients ≥65 years requiring aortic valve replacement (AVR). The aim is to compare clinical outcomes (major adverse events survival at short and long term) and resource-consumption (health resources, anticoagulation rates and post-surgery length of stay in ward -LoS- and intensive care unit -ICU-) between mechanical (MAVI) and biological aortic valve implants (BAVI) in AVR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have